Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 245

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 245
---
gesic effects for ZTlido’s approval. Mean Lidocaine Plasma Concentration Time Profiles - Semilog Scale Pivotal Adhesion Study- SCI-LIDO-ADH-001 We conducted an open-label, single-treatment, single-period, single-application adhesion performance study in 54 healthy, human subjects to assess the adhesion performance of ZTlido over the 12-houradministration period of the product. The study also investigated whether ZTlido met an FDA established adhesion performance benchmark of greater than or equal to 90% adhesion in greater than or equal to 90% of subjects in the study at the end of the administration period. At the end of the 12-houradministration period, over 90% of the subjects (49 out of the 54 subjects) maintained greater than or equal to 90% adhesion, with no adverse events reported during the study. 156

ZTlido Maintained Greater Than 90% Adhesion Over the 12-HourTime Period

This study was considered the pivotal adhesion study for marketing approval and is summarized in the
product label.

Head-to-HeadAdhesion Study versus Lidoderm- SCI-LIDO-ADH-002

We
conducted an open label, single-treatment, three-period, single-application adhesion performance study in 44 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of Lidoderm over a 12-hour administration period.

In this study, ZTlido demonstrated significantly superior mean adhesion
scores compared to Lidoderm at 3, 5, 9 and 12 hours after application. ZTlido maintained a mean percent adhesion performance greater than 90% over the 12-hour administration period, while Lidoderm fell below
90% mean adhesion within three hours.

157

ZTlido Demonstrated Superior Adhesion Compared to Lidoderm

Head-to-HeadAdhesion Study versus Mylan’s Generic - SCI-LIDO-ADH-003

We conducted an open-label, single-treatment, two-period, single-application adhesion performance study
in 24 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of a generic lidocaine patch 5% manufactured by Mylan over a 12-hour administration period. The
purpose of this study was to compare the adhesion performance of ZTlido against a topical